<?xml version="1.0" encoding="UTF-8"?>
<p>Zhou et al. [
 <xref rid="B45-molecules-25-03249" ref-type="bibr">45</xref>] suggested, also, that β-caryophyllene could be used as a therapeutic target for the treatment of diabetic patients, since this terpene acts at the level of arginine-specific mono-ADP-ribosyltransferase 1. Moreover, β-caryophyllene oral administration at a dose of 200 mg/kg induced a reduction of glucose, increase of plasma insulin levels, and improvement of altered activities of carbohydrate metabolic enzymes [
 <xref rid="B46-molecules-25-03249" ref-type="bibr">46</xref>].
</p>
